Xenon Pharmaceuticals (XENE) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
February 27, 2025 4:01 PM ESTPhase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch
First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to initiate mid-year
Phase 3 azetukalner bipolar depression program planned for clinical trial initiation mid-year
Early-stage portfolio advancing with Kv7 and Nav1.7 IND filings anticipated in 2025
Neurocrine collaboration achieves milestone with initiation of Phase 1 study of Nav1.2/Nav1.6 inhibitor
Conference call at 4:30 pm ET today
VANCOUVER,... More
